TP53 and carcinoma: The analysis of the correlation between molecular subtype and outcome in both cohorts, excluding histologic types for which the molecular classification algorithm is not valid (carcinosarcoma, undifferentiated/differentiated carcinoma, neuroendocrine carcinoma, and carcinomas of unknown histology), showed that endometrial carcinoma with abnormal p53 expression/TP53 mutation exhibited poor prognostic behaviour (Supplementary Fig. S11).